ClinicalTrials.gg
RecruitingNCT06359041Updated Oct 19, 2026

RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis

A Phase 1/2 interventional study of CABA-201 and CABA-201 in Generalized Myasthenia Gravis (gMG), sponsored by Cabaletta Bio. Recruiting at 17 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by Cabaletta Bio · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2024; still recruiting 1 year 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 144 studies in Myasthenia Gravis with a site in United States — 53 open to participants now, 73 under way, 25 of them phase 3. Myasthenia Gravis · United States.

Planned enrollment
75th of 108
24 · median 56
Started
2024
with 22 others
Phase 1/2
6 of 144
3 open now
Primary completion
2029-09
later than 54 of 72 live
Registered
102nd of 144
by date

Among the 144 studies in Myasthenia Gravis with a site in United States, this one is the 75th largest by planned enrollment of the 108 interventional ones that give a count, is one of 23 that started in 2024, is one of 6 in phase 1/2, reaches primary completion later than 54 of the 72 other live ones, and was the 102nd registered.

Myasthenia Gravis

331 studies on the registry are indexed under Myasthenia Gravis; 145 are open to participants now.

Browse Myasthenia Gravis studies →

Open to participants now

53 of the 144 studies in Myasthenia Gravis with a site in United States are open now. Recruiting first, the newest first:

48 more — sign in →

All 53 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 104 Myasthenia Gravis studies recruiting now, 64 (62%) set no upper age limit and 23 (22%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 144 studies in Myasthenia Gravis with a site in United States, or all of them as a file.
02

Study summary

RESET-MG: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Participants with Generalized Myasthenia Gravis

Read the detailed description

Myasthenia gravis (MG) is a rare autoimmune disorder characterized by autoantibody responses that cause defective transmission of signals at the neuromuscular junction, resulting in a distinctive pattern of weakness. Patients with generalized MG (gMG) typically experience symptoms associated with ocular disease in addition to weakness of many other voluntary muscle groups, including extremity, bulbar, and respiratory muscles. MG is considered a classic example of a B-cell mediated autoimmune disease. Currently, there are no curative treatments for MG. This study is being conducted to evaluate the safety and efficacy of an investigational cell therapy, CABA-201, that can be given to patients with gMG. A single dose of CABA-201 in combination with cyclophosphamide (CY) and fludarabine (FLU) will be evaluated. In addition, escalating doses of CABA-201 will be evaluated in patients without CY and FLU preconditioning.

03

Conditions studied

  • Generalized Myasthenia Gravis (gMG)

Keywords

  • CABA-201
  • autoimmune disease
  • anti-CD19 CAR-T therapy
  • cellular therapy
  • Myasthenia Gravis
  • Neuromuscular
  • Anti-AChR
  • Anti-LRP4
  • Anti-MuSK
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 and ≤70 years of age
  • Diagnosis of MG with generalized muscle weakness meeting criteria as defined by the MGFA class II, III , IVa, and IVb.
  • Diagnosis of seropositive (autoantibodies AChR, MuSK and/or LRP4) or seronegative MG

Exclusion criteria

Exclusion Criteria:

  • to leukapheresis
  • History of anaphylactic or severe systemic reaction to fludarabine, cyclophosphamide or any of their metabolites
  • Active infection requiring medical intervention at screening
  • Current symptoms of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, pulmonary, psychiatric, cardiac, neurological, or cerebral disease, including severe and uncontrolled infections, such as sepsis and opportunistic infections.
  • Concomitant medical conditions that, in the opinion of the investigator, might place the subject at unacceptable risk for participation in this study, interfere with the assessment of the effects or safety of the product or with the study procedures
  • Significant lung or cardiac impairment
  • Prior solid organ (heart, liver, kidney, lung) transplant or hematopoietic cell transplant

Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    CABA-201

    AChR Antibody-Positive Cohort or AChR Antibody-Negative Cohort

    Biological: CABA-201

  • Experimental
    CABA-201, No Preconditioning

    Infusion of CABA-201 with no preconditioning in subjects with gMG

    Biological: CABA-201

Interventions

  • BiologicalCABA-201

    Single intravenous infusion of CABA-201 at a single dose level following preconditioning with fludarabine and cyclophosphamide

  • BiologicalCABA-201

    Single intravenous infusion of CABA-201 at escalating dose levels without preconditioning

06

What researchers measure

Primary outcomes

  1. To evaluate incidence and severity of adverse events (AEs)

    An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal result of an investigation), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment. The term AE is used to include both serious and non-serious AEs.

    Time frame: Up to 28 days after CABA-201 infusion

Secondary outcomes

  1. To evaluate the incidence and severity of adverse events (AEs)

    An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal result of an investigation), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment. The term AE is used to include both serious and non-serious AEs.

    Time frame: Up to 156 weeks

  2. To characterize the pharmacodynamics (PD)

    Levels of B cells in the blood

    Time frame: Up to 156 weeks

  3. To characterize the pharmacokinetics (PK)

    Levels of CABA-201-positive T cells in the blood

    Time frame: Up to 156 weeks

  4. To evaluate disease-related biomarkers

    Levels of MG-specific autoantibodies in the serum

    Time frame: Up to 156 weeks

  5. To evaluate efficacy by change in Myasthenia Gravis - Activities of Daily Living (MG-ADL) score over time.

    The MG-ADL scale is a validated instrument administered by a qualified assessor with 8 areas of activities of daily living as reported by patients: talking, chewing, swallowing, breathing, ability to brush teeth or comb hair, ability to rise from a chair, double vision, and eyelid droop. In each area, the score ranges from 0 (normal) to 3 (most severe). The total score is the sum of all subscores.

    Time frame: Up to 156 weeks

  6. To evaluate efficacy by change in Quantitative Myasthenia Gravis (QMG) score over time.

    The QMG score is a 13-item scale conducted by a qualified assessor to evaluate disease severity in patients with MG. The total score ranges from a minimum of 0 (no myasthenic findings) to 39 (maximum myasthenic deficits).

    Time frame: Up to 156 weeks

  7. To evaluate efficacy by change in Myasthenia Gravis Composite (MGC) score over time.

    The MGC scale is a physician-reported instrument for the assessment of MG patients' symptoms and impairments. It includes 10 domains, and the total score ranges from 0 (normal) to 50 (most severe).

    Time frame: Up to 156 weeks

07

Study locations

17 of 17 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2024 (actual). Primary completion is estimated for Sep 2029, 57 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 21, 2024
First posted
Apr 11, 2024
StartActual
Dec 17, 2024
Primary completionEst.
Sep 2029
CompletionEst.
Sep 2029
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Site contacts
Changed at 4 sites. See the sites
Show 4 sites
  • University of California, San Francisco · San Francisco, United StatesContact E•••@ucsf.edu · •••3736→Z•••@ucsf.edu · •••0671
  • UC Davis, Department of Neurology · Sacramento, United StatesContact s•••@ucdavis.edu · •••1798→d•••@health.ucdavis.edu · •••1798
  • Baylor College of Medicine Neurology Department · Houston, United StatesContact v•••@bcm.edu · •••5670→r•••@bcm.edu · •••7486
  • Houston Methodist Hospital · Houston, United StatesContact d•••@houstonmethodist.org · •••8226→a•••@houstonmethodist.org · •••3639
across 2 updates, Oct 9, 2026 – Oct 19, 2026
Show all 2 updates
  1. Oct 19, 2026
    Site contacts Changed at 4 sites. See the sites
    Show 4 sites
    • UC Davis, Department of Neurology · Sacramento, United StatesContact s•••@ucdavis.edu · •••1798→d•••@health.ucdavis.edu · •••1798
    • University of California, San Francisco · San Francisco, United StatesContact E•••@ucsf.edu · •••3736→Z•••@ucsf.edu · •••0671
    • Baylor College of Medicine Neurology Department · Houston, United StatesContact v•••@bcm.edu · •••5670→r•••@bcm.edu · •••7486
    • Houston Methodist Hospital · Houston, United StatesContact d•••@houstonmethodist.org · •••8226→a•••@houstonmethodist.org · •••3639
  2. Oct 9, 2026
    Site contacts Changed at 1 site. See the sites
    Show the site
    • University of California, San Francisco · San Francisco, United StatesContact Z•••@ucsf.edu · •••0671→E•••@ucsf.edu · •••3736
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06359041
Lead sponsor
Cabaletta Bio
Responsible party
Sponsor
First posted
Apr 11, 2024
Start date
Dec 17, 2024
Primary completion
Sep 2029 (estimated)
Completion
Sep 2029 (estimated)
Last update
Oct 19, 2026

Study contacts

Cabaletta Bio
Contact
clinicaltrials@cabalettabio.com
267 759 3100 ext. 4444
Medical Director
study chair · Cabaletta Bio

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Autologous Anti-CD19 CAR-T Cells CABA-201

Start the discussion